Regulus Therapeutics Inc (RGLS) 16.85 $RGLS
Critical Alerts For Apple, Regulus Therapeutics, Intrexon, Tempur Sealy and SINA Released By InvestorsObserver
PR Newswire - Fri Feb 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, RGLS, XON, TPX and SINA.
SINA: 38.37 (+0.59), TPX: 55.62 (+1.71), XON: 39.30 (+1.05), RGLS: 16.85 (-0.13), AAPL: 127.08 (+0.62)
Regulus Announces Timing for Fourth Quarter and Year-End 2014 Financial Results Webcast and Conference Call
PR Newswire - Thu Feb 12, 4:09PM CST
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the fourth quarter and year ended December 31, 2014 on Wednesday, February 18, 2015, after the U.S. financial markets close.
RGLS: 16.85 (-0.13)
Today's Dead Cat Bounce Stock: Regulus Therapeutics (RGLS)
at The Street - Tue Feb 10, 8:48AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a "dead cat bounce" (down big yesterday but up big today) candidate
RGLS: 16.85 (-0.13)
Why Shares of Regulus Therapeutics Inc. Crashed
George Budwell, The Motley Fool - Motley Fool - Mon Feb 09, 10:55AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of Regulus Therapeutics broke down today,...
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), RGLS: 16.85 (-0.13), ABBV: 58.05 (+1.00)
Regulus' Dream of a Single-Shot Hepatitis C Cure Falls Short
at The Street - Mon Feb 09, 9:05AM CST
Whether Regulus can still succeed with a multi-shot regimen or a combination requiring a shot and daily pills will depend on results from studies not yet conducted.
GILD: 101.90 (+1.10), RGLS: 16.85 (-0.13), ABBV: 58.05 (+1.00)
Regulus Therapeutics Inc. (Nasdaq: RGLS) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Mon Feb 09, 9:00AM CST
What:
RGLS: 16.85 (-0.13), NDAQ: 49.48 (-0.27)
Data on Regulus HCV med fails to excite investors
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 8:30AM CST
RGLS: 16.85 (-0.13)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 8:12AM CST
MSI: 69.91 (-0.09), ATOS: 1.67 (+0.11), CGA: 2.02 (+0.09), DO: 35.21 (+0.36), RIOM: 3.04 (+0.06), FSC: 7.23 (+0.12), ACHN: 10.89 (-0.20), RGLS: 16.85 (-0.13), GALE: 1.68 (+0.06), NBG: 1.61 (+0.18)
All HCV Patients Treated with a Single SC Administration of 4 mg/kg of RG-101 Responded with Mean Viral Load Reduction of 4.8 log10 at Day 29 and 9/14 Patients are Below the Limit of Quantification at Day 57
PR Newswire - Mon Feb 09, 6:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"
, for the treatment of hepatitis C virus infection ("HCV" . Treatment with a single subcutaneous dose of 4 mg/kg of RG-101 as monotherapy resulted in significant and sustained viral load reductions in all patients, including difficult to treat genotypes, various liver fibrosis status and those who have experienced viral relapse after a prior IFN-containing regimen. To date, RG-101 continues to have a favorable safety profile with no serious adverse events or discontinuations reported in the treated HCV patients.
RGLS: 16.85 (-0.13)
HCV Stocks Struggle As Gilead, Merck Face Headwinds
at Investor's Business Daily - Wed Feb 04, 11:12AM CST
Stocks in the hepatitis C field were down Wednesday in the wake of Gilead Sciences' (GILD) cautious forecast while potential competitor Merck hit an FDA setback. Gilead stock plunged more than 9% in early trading as multiple analysts cut their price...
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), RGLS: 16.85 (-0.13), ABBV: 58.05 (+1.00)
Hematological Malignancies: Multiple Myeloma (MM) Market Report 2015
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/rsh8ph/hematological) has announced the addition of the "Hematological Malignancies: Multiple Myeloma (MM) " report to their offering. While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor's sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition. This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma - JP, approved). While novel targets address unmet need, the pertinent Question remains - is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts' risk profile? Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a 'right' diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues. This report highlights the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM. This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted. The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ. Key Topics Covered: 1. Executive Summary 2. Disease Overview, Diagnosis, and Current Treatment 3. Diagnostic Tools for Multiple Myeloma 4. M&A Deals and Market Opportunity in Diagnostic Space 5. Current Therapies 6. Novel Targets 7. Clinical Milestones 8. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline 9. M&A/ Licensing Deals and Unpartnered Product Opportunities Companies Mentioned - Abbott - Affymetrix - AgenaBio - Altor Bioscience - Amgen - Array Biopharma - Astex pharma (now Otsuka pharma) - BMS - Biotest pharma - Cancer Genetics Inc - Celgene - CureTech - GSK - Illumina - Immunogen - Innate Pharma - Innate Pharma - JNJ - Karyopharm Therapeutics - Lilly - Merck - MorphoSys - Mundipharma - NeoGenomics - Novartis - Pharmacyclics - Regulus Therapeutics - Rosetta Genomics - Sequenta - Takeda Pharma For more information visit http://www.researchandmarkets.com/research/rs...atological
MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), CGIX: 7.07 (unch), NVS: 102.20 (-0.17), KPTI: 27.12 (-0.13), CELGZ: 3.17 (-0.04)
Regulus to Present at Two Upcoming Investor Conferences
PR Newswire - Mon Feb 02, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 1:30 pm EST and at the 4th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 11, 2015 at 3:55 pm EST. Both conferences are being held at the Waldorf-Astoria Hotel in New York City.
RGLS: 16.85 (-0.13)
Regulus Earns Milestone Payment from Biogen Idec Related to the Identification of Potential microRNA Biomarkers in Multiple Sclerosis
PR Newswire - Mon Feb 02, 7:00AM CST
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has earned a milestone payment from Biogen Idec (NASDAQ: BIIB) related to progress in the companies' research collaboration to identify microRNAs as biomarkers for multiple sclerosis ("MS" . To earn the milestone, Regulus' microMarkersSM division used its robust technology platform to successfully meet quality specifications for extracting and reproducibly profiling microRNAs from an initial set of whole blood samples of a recent Biogen Idec MS therapy trial. Regulus' microMarkersSM division is now working to identify a microRNA biomarker signature with the potential to differentiate relapse remitting MS patients from healthy volunteers and to compare with treatment response profiles.
BIIB: 391.66 (-0.45), RGLS: 16.85 (-0.13)
5 Stocks Ready for Breakouts: Veracyte, Flextronics and More
at The Street - Fri Jan 30, 5:00AM CST
These stocks look poised to break out and trade higher from current levels.
FLEX: 12.05 (-0.09), EXXI: 4.00 (+0.42), VCYT: 8.77 (+0.22), XGTI: 0.43 (+0.01), RGLS: 16.85 (-0.13)
Can Regulus Therapeutics Double Again on Next Hep-C Drug Trial Update?
at The Street - Wed Jan 28, 1:28PM CST
New trial data from a group of hepatitis C patients treated with a higher dose of RG-101 are expected in early February, according to Regulus
GILD: 101.90 (+1.10), RGLS: 16.85 (-0.13), ABBV: 58.05 (+1.00)
Regulus Therapeutics (RGLS) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 7:47AM CST
Regulus Therapeutics (RGLS) Shares March Higher, Can It Continue?
RGLS: 16.85 (-0.13)
Should AbbVie Inc. Or Gilead Sciences Buy These Tiny Biotech Stocks?
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 12:04PM CST
Recently approved new drugs from AbbVie and Gilead Sciences means that the two biotech titans are locked in a heated battle for hepatitis C market share, but these companies may be better served shifting their attention away from this tussle...
ESRX: 84.90 (+0.40), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), RGLS: 16.85 (-0.13), ABBV: 58.05 (+1.00)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 90.70 (+0.93), ACT: 285.37 (+3.71), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), EPZM: 21.58 (+0.08), ALKS: 71.40 (-1.89), HSP: 87.35 (unch), CELG: 115.88 (+0.16), JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17)
Regulus Announces Key Goals Under its 'Clinical Map Initiative' for 2015
PR Newswire - Thu Jan 08, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced key goals for 2015 under its 'Clinical Map Initiative' to advance its microRNA therapeutics portfolio and biomarkers platform.
RGLS: 16.85 (-0.13)
How These 3 Stocks Doubled Investors' Money in Q4
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 03, 9:31AM CST
Source: Flickr user Tax Credits Most of the time, life-changing financial gains are generated over the long haul, not in the blink of an eye. However, sometimes stocks can put up jaw-dropping returns over a short period of time too. For example,...
BLUE: 90.70 (+0.93), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), OVAS: 44.32 (+0.87), GILD: 101.90 (+1.10), RGLS: 16.85 (-0.13), CELG: 115.88 (+0.16)
Critical Alerts For Apple, Regulus Therapeutics, Intrexon, Tempur Sealy and SINA Released By InvestorsObserver
PR Newswire - Fri Feb 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, RGLS, XON, TPX and SINA.
SINA: 38.37 (+0.59), TPX: 55.62 (+1.71), XON: 39.30 (+1.05), RGLS: 16.85 (-0.13), AAPL: 127.08 (+0.62)
Regulus Announces Timing for Fourth Quarter and Year-End 2014 Financial Results Webcast and Conference Call
PR Newswire - Thu Feb 12, 4:09PM CST
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the fourth quarter and year ended December 31, 2014 on Wednesday, February 18, 2015, after the U.S. financial markets close.
RGLS: 16.85 (-0.13)
Today's Dead Cat Bounce Stock: Regulus Therapeutics (RGLS)
at The Street - Tue Feb 10, 8:48AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a "dead cat bounce" (down big yesterday but up big today) candidate
RGLS: 16.85 (-0.13)
Why Shares of Regulus Therapeutics Inc. Crashed
George Budwell, The Motley Fool - Motley Fool - Mon Feb 09, 10:55AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of Regulus Therapeutics broke down today,...
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), RGLS: 16.85 (-0.13), ABBV: 58.05 (+1.00)
Regulus' Dream of a Single-Shot Hepatitis C Cure Falls Short
at The Street - Mon Feb 09, 9:05AM CST
Whether Regulus can still succeed with a multi-shot regimen or a combination requiring a shot and daily pills will depend on results from studies not yet conducted.
GILD: 101.90 (+1.10), RGLS: 16.85 (-0.13), ABBV: 58.05 (+1.00)
Regulus Therapeutics Inc. (Nasdaq: RGLS) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Mon Feb 09, 9:00AM CST
What:
RGLS: 16.85 (-0.13), NDAQ: 49.48 (-0.27)
Data on Regulus HCV med fails to excite investors
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 8:30AM CST
RGLS: 16.85 (-0.13)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 8:12AM CST
MSI: 69.91 (-0.09), ATOS: 1.67 (+0.11), CGA: 2.02 (+0.09), DO: 35.21 (+0.36), RIOM: 3.04 (+0.06), FSC: 7.23 (+0.12), ACHN: 10.89 (-0.20), RGLS: 16.85 (-0.13), GALE: 1.68 (+0.06), NBG: 1.61 (+0.18)
All HCV Patients Treated with a Single SC Administration of 4 mg/kg of RG-101 Responded with Mean Viral Load Reduction of 4.8 log10 at Day 29 and 9/14 Patients are Below the Limit of Quantification at Day 57
PR Newswire - Mon Feb 09, 6:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"
, for the treatment of hepatitis C virus infection ("HCV" . Treatment with a single subcutaneous dose of 4 mg/kg of RG-101 as monotherapy resulted in significant and sustained viral load reductions in all patients, including difficult to treat genotypes, various liver fibrosis status and those who have experienced viral relapse after a prior IFN-containing regimen. To date, RG-101 continues to have a favorable safety profile with no serious adverse events or discontinuations reported in the treated HCV patients. RGLS: 16.85 (-0.13)
HCV Stocks Struggle As Gilead, Merck Face Headwinds
at Investor's Business Daily - Wed Feb 04, 11:12AM CST
Stocks in the hepatitis C field were down Wednesday in the wake of Gilead Sciences' (GILD) cautious forecast while potential competitor Merck hit an FDA setback. Gilead stock plunged more than 9% in early trading as multiple analysts cut their price...
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), RGLS: 16.85 (-0.13), ABBV: 58.05 (+1.00)
Hematological Malignancies: Multiple Myeloma (MM) Market Report 2015
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/rsh8ph/hematological) has announced the addition of the "Hematological Malignancies: Multiple Myeloma (MM) " report to their offering. While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor's sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition. This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma - JP, approved). While novel targets address unmet need, the pertinent Question remains - is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts' risk profile? Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a 'right' diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues. This report highlights the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM. This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted. The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ. Key Topics Covered: 1. Executive Summary 2. Disease Overview, Diagnosis, and Current Treatment 3. Diagnostic Tools for Multiple Myeloma 4. M&A Deals and Market Opportunity in Diagnostic Space 5. Current Therapies 6. Novel Targets 7. Clinical Milestones 8. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline 9. M&A/ Licensing Deals and Unpartnered Product Opportunities Companies Mentioned - Abbott - Affymetrix - AgenaBio - Altor Bioscience - Amgen - Array Biopharma - Astex pharma (now Otsuka pharma) - BMS - Biotest pharma - Cancer Genetics Inc - Celgene - CureTech - GSK - Illumina - Immunogen - Innate Pharma - Innate Pharma - JNJ - Karyopharm Therapeutics - Lilly - Merck - MorphoSys - Mundipharma - NeoGenomics - Novartis - Pharmacyclics - Regulus Therapeutics - Rosetta Genomics - Sequenta - Takeda Pharma For more information visit http://www.researchandmarkets.com/research/rs...atological
MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), CGIX: 7.07 (unch), NVS: 102.20 (-0.17), KPTI: 27.12 (-0.13), CELGZ: 3.17 (-0.04)
Regulus to Present at Two Upcoming Investor Conferences
PR Newswire - Mon Feb 02, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 1:30 pm EST and at the 4th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 11, 2015 at 3:55 pm EST. Both conferences are being held at the Waldorf-Astoria Hotel in New York City.
RGLS: 16.85 (-0.13)
Regulus Earns Milestone Payment from Biogen Idec Related to the Identification of Potential microRNA Biomarkers in Multiple Sclerosis
PR Newswire - Mon Feb 02, 7:00AM CST
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has earned a milestone payment from Biogen Idec (NASDAQ: BIIB) related to progress in the companies' research collaboration to identify microRNAs as biomarkers for multiple sclerosis ("MS"
. To earn the milestone, Regulus' microMarkersSM division used its robust technology platform to successfully meet quality specifications for extracting and reproducibly profiling microRNAs from an initial set of whole blood samples of a recent Biogen Idec MS therapy trial. Regulus' microMarkersSM division is now working to identify a microRNA biomarker signature with the potential to differentiate relapse remitting MS patients from healthy volunteers and to compare with treatment response profiles. BIIB: 391.66 (-0.45), RGLS: 16.85 (-0.13)
5 Stocks Ready for Breakouts: Veracyte, Flextronics and More
at The Street - Fri Jan 30, 5:00AM CST
These stocks look poised to break out and trade higher from current levels.
FLEX: 12.05 (-0.09), EXXI: 4.00 (+0.42), VCYT: 8.77 (+0.22), XGTI: 0.43 (+0.01), RGLS: 16.85 (-0.13)
Can Regulus Therapeutics Double Again on Next Hep-C Drug Trial Update?
at The Street - Wed Jan 28, 1:28PM CST
New trial data from a group of hepatitis C patients treated with a higher dose of RG-101 are expected in early February, according to Regulus
GILD: 101.90 (+1.10), RGLS: 16.85 (-0.13), ABBV: 58.05 (+1.00)
Regulus Therapeutics (RGLS) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 7:47AM CST
Regulus Therapeutics (RGLS) Shares March Higher, Can It Continue?
RGLS: 16.85 (-0.13)
Should AbbVie Inc. Or Gilead Sciences Buy These Tiny Biotech Stocks?
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 12:04PM CST
Recently approved new drugs from AbbVie and Gilead Sciences means that the two biotech titans are locked in a heated battle for hepatitis C market share, but these companies may be better served shifting their attention away from this tussle...
ESRX: 84.90 (+0.40), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), RGLS: 16.85 (-0.13), ABBV: 58.05 (+1.00)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 90.70 (+0.93), ACT: 285.37 (+3.71), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), EPZM: 21.58 (+0.08), ALKS: 71.40 (-1.89), HSP: 87.35 (unch), CELG: 115.88 (+0.16), JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17)
Regulus Announces Key Goals Under its 'Clinical Map Initiative' for 2015
PR Newswire - Thu Jan 08, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced key goals for 2015 under its 'Clinical Map Initiative' to advance its microRNA therapeutics portfolio and biomarkers platform.
RGLS: 16.85 (-0.13)
How These 3 Stocks Doubled Investors' Money in Q4
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 03, 9:31AM CST
Source: Flickr user Tax Credits Most of the time, life-changing financial gains are generated over the long haul, not in the blink of an eye. However, sometimes stocks can put up jaw-dropping returns over a short period of time too. For example,...
BLUE: 90.70 (+0.93), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), OVAS: 44.32 (+0.87), GILD: 101.90 (+1.10), RGLS: 16.85 (-0.13), CELG: 115.88 (+0.16)
